Combination versus monotherapy as definitive treatment for Pseudomonas aeruginosa bacteraemia: a multicentre retrospective observational cohort study.
Tanya BabichPontus NauclerJohn Karlsson ValikChristian G GiskeNatividad BenitoRuben CardonaAlba RiveraCeline PulciniManal Abdel FattahJustine HaquinAlasdair MacGowanSally GrierJulie GibbsBibiana ChazanAnna YanovskayRonen Ben AmiMichal LandesLior NesherAdi Zaidman-ShimshovitzKate McCarthyDavid L PatersonEvelina TacconelliMichael BuhlSusanna MauerJesús Rodríguez-BañoIsabel MoralesAntonio OliverEnrique Ruiz de GopeguiAngela CanoIsabel MachucaMonica Gozalo-MarguelloLuis Martinez MartinezEva M Gonzalez-BarberaIris Gomez AlfaroMiguel SalavertBojana BeovicAndreja SajeManica Mueller-PremruLeonardo PaganiVirginie VitratDiamantis P KofteridisMaria ZacharioudakiSofia MarakiYulia WeissmanMical PaulYaakov DicksteinLeonard LeiboviciDafna YahavPublished in: The Journal of antimicrobial chemotherapy (2021)
In this retrospective cohort, no mortality advantage was demonstrated using combination therapy over monotherapy for P. aeruginosa bacteraemia. Combination therapy did not improve clinical or microbiological failure rates, nor affect adverse events or resistance development. Our finding of no benefit with combination therapy needs confirmation in well-designed randomized controlled trials.